309 results on '"Orfanos, S."'
Search Results
102. Tissue microdialysis in critically ill septic patients: associations with sepsis severity and mortality
- Author
-
Theodorakopoulou, M, primary, Orfanos, S, additional, Diamantakis, A, additional, Tsafou, E, additional, Karkouli, G, additional, Nikitas, N, additional, Ikonomidis, I, additional, Ilias, I, additional, Tsangaris, I, additional, Armaganidis, A, additional, and Dimopoulou, I, additional
- Published
- 2010
- Full Text
- View/download PDF
103. Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy?
- Author
-
Orfanos, S. E., primary and Langleben, D., additional
- Published
- 2009
- Full Text
- View/download PDF
104. Venous oxygen saturation and lactate gradient from the superior vena cava to the pulmonary artery in ICU patients with septic shock
- Author
-
Kopterides, P, primary, Mavrou, I, additional, Kostadima, E, additional, Zakynthinos, E, additional, Lignos, M, additional, Kontopithari, G, additional, Papadomichelakis, E, additional, Theodorakopoulou, M, additional, Tsangaris, I, additional, Dimopoulos, G, additional, Dimopoulou, I, additional, Orfanos, S, additional, Bonovas, S, additional, and Armaganidis, A, additional
- Published
- 2009
- Full Text
- View/download PDF
105. Serum of patients with septic shock stimulates the expression of Trem-1 on U937 monocytes
- Author
-
Dimopoulou, I., primary, Orfanos, S. E., additional, Pelekanou, A., additional, Kotanidou, A., additional, Livaditi, O., additional, Augustatou, C., additional, Zervou, M., additional, Douka, E., additional, Theodorakopoulou, M., additional, Karagianni, V., additional, Douzinas, E., additional, Armaganidis, A., additional, and Giamarellos-Bourboulis, E. J., additional
- Published
- 2008
- Full Text
- View/download PDF
106. Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein
- Author
-
Orfanos, S. E., primary and Zakynthinos, S., additional
- Published
- 2008
- Full Text
- View/download PDF
107. Prognostic value of plasma amino-terminal pro-brain natriuretic peptide in a large, representative ICU population
- Author
-
Kotanidou, A, primary, Karsaliakos, P, additional, Tzanela, M, additional, Mavrou, I, additional, Kopterides, P, additional, Papadomichelakis, E, additional, Theodorakopoulou, M, additional, Tsagaris, I, additional, Lignos, M, additional, Ikonomidis, I, additional, Ilias, I, additional, Armaganidis, A, additional, Orfanos, S, additional, and Dimopoulou, I, additional
- Published
- 2008
- Full Text
- View/download PDF
108. Systemic markers of inflammation in mechanically ventilated brain-injured patients in the absence of sepsis and acute lung injury: the effect of positive end-expiratory pressure
- Author
-
Korovesi, I, primary, Kotanidou, A, additional, Papadomichelakis, E, additional, Giamarellos-Bourboulis, E, additional, Pelekanou, A, additional, Livaditi, O, additional, Sotiropoulou, C, additional, Koutsoukou, A, additional, Dimopoulou, I, additional, Armaganidis, A, additional, Roussos, C, additional, Marczin, N, additional, and Orfanos, S, additional
- Published
- 2008
- Full Text
- View/download PDF
109. The relation of thyroid hormone levels and reduced insulin sensitivity to survival of patients with septic shock
- Author
-
Halvatsiotis, PG, primary, Stefanopoulou, S, additional, Kotanidou, A, additional, Orfanos, S, additional, Martinos, C, additional, Roussos, C, additional, Economopoulos, T, additional, and Raptis, SA, additional
- Published
- 2007
- Full Text
- View/download PDF
110. O101 A proposed mechanism of action of glucocorticosteroids in severe sepsis
- Author
-
Giamarellos-Bourboulis, E., primary, Orfanos, S., additional, Pelekanou, A., additional, Kotanidou, A., additional, Tzepi, I., additional, Armaganidis, A., additional, Spyridaki, E., additional, and Dimopoulou, I., additional
- Published
- 2007
- Full Text
- View/download PDF
111. Low sensitivity of measurements of respiratory mechanics in detecting lung edema from high tidal volume mechanical ventilation
- Author
-
Maniatis, N, primary, Orfanos, S, additional, Roussos, H, additional, Armaganidis, A, additional, and Kotanidou, A, additional
- Published
- 2007
- Full Text
- View/download PDF
112. Exhaled breath condensate mediators in mechanically ventilated brain-injured patients with no acute lung injury are mostly related to markers of systemic inflammation
- Author
-
Korovesi, I, primary, Papadomichelakis, E, additional, Livaditi, O, additional, Giamarellos-Bourboulis, E, additional, Sotiropoulou, C, additional, Koutsoukou, A, additional, Dimopoulou, I, additional, Armaganidis, A, additional, Roussos, C, additional, Marczin, N, additional, Kotanidou, A, additional, and Orfanos, S, additional
- Published
- 2007
- Full Text
- View/download PDF
113. Growth curves for body weight and carcass components, and carcass composition of the Karagouniko sheep, from birth to 720d of age
- Author
-
Goliomytis, M., primary, Orfanos, S., additional, Panopoulou, E., additional, and Rogdakis, E., additional
- Published
- 2006
- Full Text
- View/download PDF
114. Reproducibility of the low-dose corticotropin (ACTH) stimulation test in ICU patients with sepsis and/or septic shock
- Author
-
Dimopoulou, I, Zervou, M, Douka, E, Augustatou, C, Alevizopoulou, P, Stamoulis, K, Theodorakopoulou, M, Mavrou, I, Lignos, M, Kopterides, P, Papadomichelakis, E, Tzoufi, M, Orfanos, S, Tzanela, M, Armaganidis, A, Tsagarakis, S, and Roussos, C
- Subjects
Poster Presentation - Published
- 2006
115. Hypothalamic-pituitary-adrenal axis in mechanically ventilated critically ill patients: incidence of hyporesponsiveness to stimulation and relationship to cytokine levels
- Author
-
Dimopoulou, I, Alevizopoulou, P, Livaditi, O, Souvatzoglou, E, Orfanos, S, Tzanela, M, Kotanidou, A, Mavrou, I, Kopterides, P, Lignos, M, Theodorakopoulou, M, Papadomichelakis, E, Tzoufi, M, Tsangaris, H, Thalassinos, N, Armaganidis, A, Roussos, C, and Tsagarakis, S
- Subjects
Poster Presentation - Published
- 2006
116. Relative adrenal insufficiency after major abdominal surgery
- Author
-
Dimopoulou, I, Mavrou, I, Douka, E, Lyberopoulos, P, Kopterides, P, Orfanos, S, Tzanela, M, Lignos, M, Theodorakopoulou, M, Augustatou, C, Kostopanagiotou, G, Macheras, A, Vasdekis, S, Thalassinos, N, Tsagarakis, S, and Armaganidis, A
- Subjects
Poster Presentation - Published
- 2006
117. Cortisol and dehydroepiandrosterone sulphate levels in ICU patients upon admission correlate with severity of disease
- Author
-
Dimopoulou, I, Stamoulis, K, Lyberopoulos, P, Alevizopoulou, P, Theodorakopoulou, M, Orfanos, S, Tzanela, M, Kopterides, P, Lignos, M, Papadomichelakis, E, Mavrou, I, Tzoufi, M, Tsangaris, H, Armaganidis, A, Thalassinos, N, Tsagarakis, S, and Roussos, C
- Subjects
Poster Presentation - Published
- 2006
118. Endocrine responses to major abdominal surgery
- Author
-
Dimopoulou, I, Douka, E, Mavrou, I, Kopterides, P, Lignos, M, Lyberopoulos, P, Augustatou, C, Tzanella, M, Orfanos, S, Macheras, A, Kostopanagiotou, G, Trivizas, P, Potoula, E, Thalassinos, N, Tsagarakis, S, and Armaganidis, A
- Subjects
Poster Presentation - Published
- 2005
119. The time course of adrenocortical hormones and cytokines in sepsis and/or septic shock
- Author
-
Dimopoulou, I, Tsagarakis, S, Zervou, M, Douka, E, Orfanos, S, Kotanidou, A, Livaditi, O, Augustatou, C, Tzanella, M, Thalassinos, N, Armaganidis, A, and Roussos, C
- Subjects
Poster Presentation - Published
- 2005
120. Pulmonary endothelium in acute lung injury: from basic science to the critically ill.
- Author
-
Pinsky, Michael R., Brochard, Laurent, Mancebo, Jordi, Orfanos, S. E., Mavrommati, I., Korovesi, I., and Roussos, C.
- Published
- 2006
- Full Text
- View/download PDF
121. Adrenal hyporesponsiveness to the low-dose stimulation test (LDST) is associated with a higher mortality in early sepsis and/or septic shock
- Author
-
Dimopoulou, I, Zervou, M, Tsagarakis, S, Duka, E, Augustatou, C, Tzanela, M, Orfanos, S, Alevizopoulou, P, Thalassinos, N, and Roussos, C
- Subjects
Poster Presentation - Published
- 2004
122. Primary retroperitoneal mucinous cystadenoma. A rare case with two cysts and review of the literature.
- Author
-
Paraskevakou, H, Orfanos, S, Diamantis, T, Konstantinidou, A, and Patsouris, E
- Subjects
- *
RETROPERITONEAL fibrosis , *CYSTS (Pathology) , *CYSTADENOMA , *ADENOMA , *IMMUNOSTAINING - Abstract
Background: Primary retroperitoneal mucinous cystadenoma is a rare neoplasm, with benign biological behavior. Delay in diagnosis and treatment of this tumor may be fatal for the patient, because of complications, such as rupture, infection and malignant transformation. Case presentation: We present a 23-year-old woman, who was admitted to the hospital because of a palpable abdominal mass and discomfort since 4 months. Computed Tomography and Magnetic Resonance Imaging scans were performed and showed two retroperitoneal cystic masses, which were excised by laparoscopy. Histological and immunohistochemical examination revealed that the inner surfaces of the cysts were lined by epithelium with features of mesothelial cells, in addition to ovarian mucinous cystadenoma. This is the 29th case and the second reported case with two contemporary cysts. Conclusion: The origin of retroperitoneal mucinous cystadenomas is still unclear. Pathological and immunohistochemical findings proved that these tumors resemble ovarian mucinous cystadenomas but are unattached to the ovary and can arise at any location in the retroperitoneum. Surgical excision of the aforementioned tumors is the treatment of choice. Hippokratia 2014; 18 (3): 278-281. [ABSTRACT FROM AUTHOR]
- Published
- 2014
123. High incidence of decreased cortisol reserve in brain-dead potential organ-donors
- Author
-
Dimopoulou, I, Anthi, A, Milou, E, Ilias, I, Stavrakaki, C, Tzanela, M, Orfanos, S, Christoforaki, M, Mandragos, K, Roussos, C, and Tsagarakis, S
- Subjects
Meeting Abstract - Published
- 2002
124. Effect of high blood flow on pulmonary vascular permeability to protein
- Author
-
Ehrhart, I. C., primary, McCloud, L. L., additional, Orfanos, S. E., additional, Catravas, J. D., additional, and Hofman, W. F., additional
- Published
- 1994
- Full Text
- View/download PDF
125. Effects of indomethacin on PMA-induced pulmonary endothelial enzyme dysfunction in vivo
- Author
-
Chen, X., primary, Orfanos, S. E., additional, and Catravas, J. D., additional
- Published
- 1992
- Full Text
- View/download PDF
126. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.
- Author
-
Orfanos, S E, Armaganidis, A, Glynos, C, Psevdi, E, Kaltsas, P, Sarafidou, P, Catravas, J D, Dafni, U G, Langleben, D, and Roussos, C
- Published
- 2000
127. Species variation in pulmonary endothelial aminopeptidase P activity.
- Author
-
Chen, X, Orfanos, S E, Ryan, J W, Chung, A Y, Hess, D C, and Catravas, J D
- Abstract
Pulmonary endothelial aminopeptidase P (AmP) may be an important contributor to the inactivation of circulating bradykinin in certain species. To examine this possibility, we measured AMP activity in vivo and in vitro using Arg-Pro-Pro-[3H]benzylamide (3H-APPB) as substrate under conditions of first order enzyme kinetics. Utilizing multiple indicator dilution techniques, metabolism of 3H-APPB to Arg and Pro-Pro-[3H]benzylamide by AmP was not detectable during a single transpulmonary passage in anesthetized rabbits (n = 4), cats (n = 3) and pigs (n = 4). However, percent metabolism of 3H-APPB ranged from 54 to 63% in anesthetized rats (n = 6). In all experiments, the substrate remained within the vascular space and was thus accessible to endothelial and blood AmP only. At the same time, single-pass transpulmonary percent metabolism of [14C]benzoyl-Ala-Gly-Pro by endothelial-bound angiotensin converting enzyme was remarkably similar among rabbits, cats, rats and pigs (60-65%). In culture, Vmax/Km of AmP was 3 to 10 x 10(-4) min-1 for human basal arterial and rabbit and bovine pulmonary arterial endothelial cell monolayers (2 x 10(5) cells). AmP activity in the supernatant of lung and kidney tissue (homogenized in saline containing 1-o-n-octyl-beta-glucopyranoside) from rabbit, cat, pig and rat expressed as Vmax/Km(min-1) per (g wet tissue/ml) was 0.74, 2.25, 3.91 and 185.8 (lung), and 1.0, 3.7, 8.4 and 438.3 (kidney), respectively. Similarly, Vmax/Km values of AmP in plasmas of cat, dog, rabbit, pig, calf (serum), human and rat were 0, 0.016, 0.025, 0.068, 0.191, 0.237 and 3.53 min-1. These results suggest that 1) there are large interspecies variations in AmP activities of plasma, lung and kidney; 2) of the species studied, the rat contains the largest activities of AmP; and 3) AmP appears to be located on the luminal surface of the rat pulmonary endothelium.
- Published
- 1991
128. Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?
- Author
-
Pavlidis, Nicholas, Nikolaou, N., Ch, F. Tolis, Orfanos, S., Tolis, G., and Pavlidis, Nicholas [0000-0002-2195-9961]
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_treatment ,Endogeny ,Disease ,Hypogonadotropic hypogonadism ,Bone Marrow ,Antineoplastic Combined Chemotherapy Protocols ,Nandrolone ,Testosterone ,Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use ,Bone Marrow Diseases ,Cancer ,Priority journal ,Bone marrow diseases ,Myelosuppression androgens ,Bone Marrow/drug effects ,Hodgkin Disease ,medicine.anatomical_structure ,Mechlorethamine/administration & dosage/adverse effects ,Vincristine ,Cancer chemotherapy ,Testosterone/*therapeutic use ,Vincristine/administration & dosage/adverse effects ,Hypogonadism/complications/*drug therapy ,Pituitary Hormone-Releasing Hormones ,Human ,medicine.medical_specialty ,Hodgkin disease ,Bone marrow suppression ,medicine.drug_class ,Gonadotropin releasing hormone deficiency ,Bone Marrow Diseases/*chemically induced/drug therapy ,Pituitary hormone-releasing hormones ,Prednisone/administration & dosage/adverse effects ,Disease association ,Antineoplastic combined chemotherapy protocols ,Internal medicine ,Case report ,medicine ,Humans ,Bone marrow ,Mechlorethamine ,Aged ,Chemotherapy ,business.industry ,Hypogonadism ,fungi ,Chlormethine ,Androgen ,medicine.disease ,Pituitary Hormone-Releasing Hormones/deficiency ,Endocrinology ,Procarbazine ,Hodgkin Disease/complications/*drug therapy ,Pediatrics, Perinatology and Child Health ,Prednisone ,Procarbazine/administration & dosage/adverse effects ,business - Abstract
A patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described. Chemotherapy administration caused prolonged and life‐threatening myelosuppression; androgen substitution seemed to reverse bone marrow function and to maintain normal peripheral blood counts. Whether or not androgens are a necessary substitution in hypogonadal patients suffering from cancer and undergoing chemotherapy is discussed. Copyright © 1989 Wiley‐Liss, Inc., A Wiley Company 17 3 222 226
- Published
- 1989
129. This title is unavailable for guests, please login to see more information.
130. Intercomparison of three recruitment maneuvers in acute respiratory distress syndrome: The role of body mass index
- Author
-
Katsiari, M., NIKOLAOS KOULOURIS, Orfanos, S. E., Maguina, N., Sotiropoulou, C., and Koutsoukou, A.
131. Elevated soluble endothelial protein C receptor levels at ICU admission are associated with sepsis development
- Author
-
Vassiliou, A. G., Kotanidou, A., Mastora, Z., Maniatis, N. A., Albani, P., Edison Jahaj, Koutsoukou, A., Armaganidis, A., and Orfanos, S. E.
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Critical Care ,Critical Illness ,Multiple Organ Failure ,Endothelial Protein C Receptor ,Receptors, Cell Surface ,Middle Aged ,Prognosis ,Young Adult ,Antigens, CD ,Predictive Value of Tests ,Risk Factors ,Sepsis ,Humans ,Female ,Aged - Abstract
The endothelial protein C receptor (EPCR) is a protein that regulates the protein C anticoagulant and anti-inflammatory pathways. A soluble form of EPCR (sEPCR) circulates in plasma and inhibits activated protein C (APC) activities. The clinical impact of sEPCR and its involvement in the septic process is under investigation. In this study, we assessed the role of sEPCR levels as an early indicator of sepsis development.Plasma sEPCR levels were measured in 59 critically-ill non-septic patients at the time of admission to the intensive care unit (ICU). Multiple logistic regression analysis was performed to identify potential risk factors for sepsis development and Cox-Regression models were fitted for variables to examine their relationship with time to sepsis development.Thirty patients subsequently developed sepsis and 29 did not. At ICU admission, sequential organ failure assessment (SOFA) scores were significantly higher in the subsequent sepsis group as compared to the non sepsis group (mean ± SD: 6.4±2.7 and 5±2.3, respectively, P=0.037). sEPCR levels were also higher in the patients who subsequently developed sepsis compared to the patients who did not (median and interquartile range: 173.4 [104.5-223.5] ng/mL vs. 98.3 [69.8-147.7] ng/mL, respectively; P=0.004). Cox regression analysis identified sEPCR as the only parameter related to sepsis development with time (relative risk: 1.078, 95% confidence interval: 1.016-1.144, by 10 units; P=0.013).Upon ICU admission, sEPCR levels in initially non-septic critically-ill patients appear elevated in the subjects who will subsequently become septic.
132. 37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3)
- Author
-
Von Seth, M., Hillered, L., Otterbeck, A., Hanslin, K., Larsson, A., Sjölin, J., Lipcsey, M., Cove, ME, Chew, N. S., Vu, L. H., Lim, R. Z., Puthucheary, Z., Wilske, F., Skorup, P., Tano, E., Derese, I., Thiessen, S., Derde, S., Dufour, T., Pauwels, L., Bekhuis, Y., Van den Berghe, G., Vanhorebeek, I., Khan, M., Dwivedi, D., Zhou, J., Prat, A., Seidah, N. G., Liaw, P. C., Fox-Robichaud, A. E., Correa, T., Pereira, J, Takala, J, Jakob, S, Maudsdotter, L., Castegren, M., Sjölin, J, Xue, M., Xu, J. Y., Liu, L., Huang, Y. Z., Guo, F. M., Yang, Y., Qiu, H. B., Kuzovlev, A., Moroz, V., Goloubev, A., Myazin, A., Chumachenko, A., Pisarev, V., Takeyama, N., Tsuda, M., Kanou, H., Aoki, R., Kajita, Y., Hashiba, M., Terashima, T., Tomino, A., Davies, R., O’Dea, K. P., Soni, S., Ward, J. K., O’Callaghan, D. J., Takata, M., Gordon, A. C., Wilson, J., Zhao, Y., Singer, M., Spencer, J., Shankar-Hari, M., Genga, K. Roveran, Lo, C., Cirstea, M. S., Walley, K. R., Russell, J. A., Linder, A., Boyd, J. H., Sedlag, A., Riedel, C., Georgieff, M., Barth, E., Bracht, H., Essig, A., Henne-Bruns, D., Gebhard, F., Orend, K., Halatsch, M., Weiss, M., Chase, M., Freinkman, E., Uber, A., Liu, X., Cocchi, M. N., Donnino, M. W., Peetermans, M., Liesenborghs, L., Claes, J., Vanassche, T., Hoylaerts, M., Jacquemin, M., Vanhoorelbeke, K., De Meyer, S., Verhamme, P., Vögeli, A., Ottiger, M., Meier, M., Steuer, C., Bernasconi, L., Huber, A., Christ-Crain, M., Henzen, C., Hoess, C., Thomann, R., Zimmerli, W., Müller, B., Schütz, P., Hoppensteadt, D., Walborn, A., Rondina, M., Tsuruta, K., Fareed, J., Tachyla, S., Ikeda, T., Ono, S., Ueno, T., Suda, S., Nagura, T., Damiani, E., Domizi, R., Scorcella, C., Tondi, S., Pierantozzi, S., Ciucani, S., Mininno, N., Adrario, E., Pelaia, P., Donati, A., Andersen, M. Schou, Lu, S., Lopez, G, Lassen, AT, Ghiran, I., Shapiro, N. I., Trahtemberg, U., Sviri, S., Beil, M., Agur, Z., Van Heerden, P., Jahaj, E., Vassiliou, A., Mastora, Z., Orfanos, S. E., Kotanidou, A., Wirz, Y., Sager, R., Amin, D., Amin, A., Haubitz, S., Hausfater, P., Kutz, A., Mueller, B., Schuetz, P., Sager, R. S., Wirz, Y. W., Amin, D. A., Amin, A. A., Hausfater, P. H., Huber, A. H., Mueller, B, Schuetz, P, Gottin, L., Dell’amore, C., Stringari, G., Cogo, G., Ceolagraziadei, M., Sommavilla, M., Soldani, F., Polati, E., Baumgartner, T., Zurauskaité, G., Gupta, S., Devendra, A., Mandaci, D., Eren, G., Ozturk, F., Emir, N., Hergunsel, O., Azaiez, S., Khedher, S., Maaoui, A., Salem, M., Chernevskaya, E., Beloborodova, N., Bedova, A., Sarshor, Y. U., Pautova, A., Gusarov, V., Öveges, N., László, I., Forgács, M., Kiss, T., Hankovszky, P., Palágyi, P., Bebes, A., Gubán, B., Földesi, I., Araczki, Á., Telkes, M., Ondrik, Z., Helyes, Z., Kemény, Á., Molnár, Z., Spanuth, E., Ebelt, H., Ivandic, B., Thomae, R., Werdan, K., El-Shafie, M., Taema, K., El-Hallag, M., Kandeel, A., Tayeh, O., Eldesouky, M., Omara, A., Winkler, M. S., Holzmann, M., Nierhaus, A., Mudersbach, E., Schwedhelm, E., Daum, G., Kluge, S., Zoellner, C., Greiwe, G., Sawari, H., Kubitz, J., Jung, R., Reichenspurner, H., Groznik, M., Ihan, A., Andersen, L. W., Holmberg, M. J., Wulff, A., Balci, C., Haliloglu, M., Bilgili, B., Bilgin, H., Kasapoglu, U., Sayan, I., Süzer, M., Mulazımoglu, L., Cinel, I., Patel, V., Shah, S., Parulekar, P., Minton, C., Patel, J., Ejimofo, C., Choi, H., Costa, R., Caruso, P., Nassar, P., Fu, J., Jin, J., Xu, Y., Kong, J., Wu, D., Yaguchi, A., Klonis, A., Ganguly, S., Kollef, M., Burnham, C., Fuller, B., Mavrommati, A., Chatzilia, D., Salla, E., Papadaki, E., Kamariotis, S., Christodoulatos, S., Stylianakis, A., Alamanos, G., Simoes, M., Trigo, E., Silva, N., Martins, P., Pimentel, J., Baily, D., Curran, L. A., Ahmadnia, E., Patel, B. V., Adukauskiene, D., Cyziute, J, Adukauskaite, A., Pentiokiniene, D., Righetti, F., Colombaroli, E., Castellano, G., Man, M., Shum, H. P., Chan, Y. H., Chan, K. C., Yan, W. W., Lee, R. A., Lau, S. K., Dilokpattanamongkol, P., Thirapakpoomanunt, P., Anakkamaetee, R., Montakantikul, P., Tangsujaritvijit, V., Sinha, S., Pati, J., Sahu, S., Valanciene, D., Dambrauskiene, A., Hernandez, K., Lopez, T., Saca, D., Bello, M., Mahmood, W., Hamed, K., Al Badi, N., AlThawadi, S., Al Hosaini, S., Salahuddin, N., Cilloniz, C. C., Ceccato, A. C., Bassi, G. L. Li, Ferrer, M. F., Gabarrus, A. G., Ranzani, O. R., Jose, A. S. San, Vidal, C. G. Garcia, de la Bella Casa, J. P. Puig, Blasi, F. B., Torres, AT, Ciginskiene, A., Simoliuniene, R., Giuliano, G., Triunfio, D., Sozio, E., Taddei, E., Brogi, E., Sbrana, F., Ripoli, A., Bertolino, G., Tascini, C., Forfori, F., Fleischmann, C., Goldfarb, D., Schlattmann, P., Schlapbach, L., Kissoon, N., Baykara, N., Akalin, H., Arslantas, M. Kemal, Gavrilovic, S. G., Vukoja, M. V., Hache, M. H., Kashyap, R. K., Dong, Y. D., Gajic, O. G., Ranzani, O., Harrison, D., Rabello, L., Rowan, K., Salluh, J., Soares, M., Markota, A. M., Fluher, J. F., Kogler, D. K., Borovšak, Z. B., Sinkovic, A. S., Siddiqui, Z, Aggarwal, P., Iqbal, O., Lewis, M., Wasmund, R., Abro, S., Raghuvir, S., Barie, P. S., Fineberg, D., Radford, A., Casazza, A., Vilardo, A., Bellazzi, E., Boschi, R., Ciprandi, D., Gigliuto, C., Preda, R., Vanzino, R., Vetere, M., Carnevale, L., Kyriazopoulou, E., Pistiki, A., Routsi, C., Tsangaris, I., Giamarellos-Bourboulis, E., Pnevmatikos, I., Vlachogiannis, G., Antoniadou, E., Mandragos, K., Armaganidis, A., Allan, P., Oehmen, R., Luo, J., Ellis, C., Latham, P., Newman, J., Pritchett, C., Pandya, D., Cripps, A., Harris, S., Jadav, M., Langford, R., Ko, B., Park, H., Beumer, C. M., Koch, R., Beuningen, D. V., Oudelashof, A. M., Vd Veerdonk, F. L., Kolwijck, E., VanderHoeven, J. G., Bergmans, D. C., Hoedemaekers, C., Brandt, J. B., Golej, J., Burda, G., Mostafa, G., Schneider, A., Vargha, R., Hermon, M., Levin, P., Broyer, C, Assous, M., Wiener-Well, Y., Dahan, M., Benenson, S., Ben-Chetrit, E, Faux, A., Sherazi, R., Sethi, A., Saha, S., Kiselevskiy, M., Gromova, E., Loginov, S., Tchikileva, I., Dolzhikova, Y., Krotenko, N., Vlasenko, R., Anisimova, N., Spadaro, S., Fogagnolo, A., Remelli, F., Alvisi, V., Romanello, A., Marangoni, E., Volta, C., Degrassi, A., Mearelli, F., Casarsa, C., Fiotti, N., Biolo, G., Cariqueo, M., Luengo, C., Galvez, R., Romero, C., Cornejo, R., Llanos, O., Estuardo, N., Alarcon, P., Magazi, B., Khan, S., Pasipanodya, J., Eriksson, M., Strandberg, G., Lipsey, M., Rajput, Z., Hiscock, F., Karadag, T., Uwagwu, J., Jain, S., Molokhia, A., Barrasa, H., Soraluce, A., Uson, E., Rodriguez, A., Isla, A., Martin, A., Fernández, B., Fonseca, F., Sánchez-Izquierdo, J. A., Maynar, F. J., Kaffarnik, M., Alraish, R., Frey, O., Roehr, A., Stockmann, M., Wicha, S., Shortridge, D., Castanheira, M., Sader, H. S., Streit, J. M., Flamm, R. K., Falsetta, K., Lam, T., Reidt, S., Jancik, J., Kinoshita, T., Yoshimura, J., Yamakawa, K., Fujimi, S., Torres, A., Zakynthinos, S., Mandragos, C., Ramirez, P., De la Torre-Prados, M., Dale, G., Wach, A., Beni, L., Hooftman, L., Zwingelstein, C., François, B., Colin, G., Dequin, P. F., Laterre, P. F., Perez, A., Welte, R., Lorenz, I., Eller, P., Joannidis, M., Bellmann, R., Lim, S., Chana, S., Patel, S., Higuera, J., Cabestrero, D., Rey, L., Narváez, G., Blandino, A., Aroca, M., Saéz, S., De Pablo, R, Albert, C. Nadège, Langouche, L., Goossens, C., Peersman, N., Vermeersch, P., Vander Perre, S., Holst, J., Wouters, P., Uber, A. U., Holmberg, M., Konanki, V., McNaughton, M., Zhang, J., Demirkiran, O., Byelyalov, A., Guerrero, J., Cariqueo, M, Rossini, N., Falanga, U., Monaldi, V., Cole, O., Scawn, N., Balciunas, M., Blascovics, I., Vuylsteke, A., Salaunkey, K., Omar, A., Salama, A., Allam, M., Alkhulaifi, A., Verstraete, S., Van Puffelen, E., Ingels, C., Verbruggen, S., Joosten, K., Hanot, J., Guerra, G., Vlasselaers, D., Lin, J., Haines, R., Zolfaghari, P., Hewson, R., Offiah, C., Prowle, J., Buter, H., Veenstra, J. A., Koopmans, M., Boerma, E. C., Taha, A., Shafie, A., Hallaj, S., Gharaibeh, D., Hon, H., Bizrane, M., El Khattate, A. A., Madani, N., Abouqal, R., Belayachi, J., Kongpolprom, N., Sanguanwong, N., Sanaie, S., Mahmoodpoor, A., Hamishehkar, H., Biderman, P., Avitzur, Y., Solomon, S., Iakobishvili, Z., Carmi, U., Gorfil, D, Singer, P., Paisley, C., Patrick-Heselton, J., Mogk, M., Humphreys, J., Welters, I., Casarotta, E., Bolognini, S., Moskowitz, A., Patel, P., Grossestreuer, A., Malinverni, S., Goedeme, D., Mols, P., Langlois, P. L., Szwec, C., D’Aragon, F., Heyland, D. K., Manzanares, W., Langlois, P., Aramendi, I., Heyland, D., Stankovic, N., Nadler, J., Sanchez, L., Wolfe, R., Donnino, M., Cocchi, M., Atalan, H. K., Gucyetmez, B., Kavlak, M. E., Aslan, S., Kargi, A., Yazici, S., Donmez, R., Polat, K. Y., Piechota, M, Piechota, A., Misztal, M., Bernas, S., Pietraszek-Grzywaczewska, I., Saleh, M., Hamdy, A., Elhallag, M., Atar, F., Kundakci, A., Gedik, E., Sahinturk, H., Zeyneloglu, P., Pirat, A., Popescu, M., Tomescu, D., Van Gassel, R., Baggerman, M., Schaap, F., Bol, M., Nicolaes, G., Beurskens, D., Damink, S. Olde, Van de Poll, M., Horibe, M., Sasaki, M., Sanui, M., Iwasaki, E., Sawano, H., Goto, T., Ikeura, T., Hamada, T., Oda, T., Mayumi, T., Kanai, T., Kjøsen, G., Horneland, R., Rydenfelt, K., Aandahl, E., Tønnessen, T., Haugaa, H., Lockett, P., Evans, L., Somerset, L., Ker-Reid, F., Laver, S., Courtney, E., Dalton, S., Georgiou, A., Robinson, K., Haas, B., Bartlett, K., Bigwood, M., Hanley, R., Morgan, P., Marouli, D., Chatzimichali, A., Kolyvaki, S., Panteli, A., Diamantaki, E., Pediaditis, E., Sirogianni, P., Ginos, P., Kondili, E., Georgopoulos, D., Askitopoulou, H., Zampieri, F. G., Liborio, A. B., Besen, B. A., Cavalcanti, A. B., Dominedò, C., Dell’Anna, A. M., Monayer, A., Grieco, D. L., Barelli, R., Cutuli, S. L., Maddalena, A. Ionescu, Picconi, E., Sonnino, C., Sandroni, C., Antonelli, M., Tuzuner, F., Cakar, N., Jacob, M., Sahu, S, Singh, Y. P., Mehta, Y., Yang, K. Y., Kuo, S., Rai, V., Cheng, T., Ertmer, C., Czempik, P, Hutchings, S., Watts, S., Wilson, C., Burton, C., Kirkman, E., Drennan, D., O’Prey, A., MacKay, A., Forrest, R., Oglinda, A., Ciobanu, G., Casian, M., Oglinda, C., Lun, C. T., Yuen, H. J., Ng, G., Leung, A., So, S. O., Chan, H. S., Lai, K. Y., Sanguanwit, P., Charoensuk, W., Phakdeekitcharoen, B., Batres-Baires, G., Kammerzell, I., Lahmer, T., Mayr, U., Schmid, R., Huber, W., Bomberg, H., Klingele, M., Groesdonk, H., Piechota, M., Mirkiewicz, K., Pérez, A. González, Silva, J., Ramos, A., Acharta, F., Perezlindo, M., Lovesio, L., Antonelli, P. Gauna, Dogliotti, A., Lovesio, C., Baron, J., Schiefer, J., Baron, D. M., Faybik, P., Chan, T. M., Ginos, P, Vicka, V., Gineityte, D., Ringaitiene, D., Sipylaite, J., Pekarskiene, J., Beurskens, D. M., Van Smaalen, T. C., Hoogland, P., Winkens, B., Christiaans, M. H., Reutelingsperger, C. P., Van Heurn, E., Nicolaes, G. A., Schmitt, F. S., Salgado, E. S., Friebe, J. F., Fleming, T. F., Zemva, J. Z., Schmoch, T. S., Uhle, F. U., Kihm, L. K., Morath, C. M., Nusshag, C. N., Zeier, M. Z., Bruckner, T. B., Mehrabi, A. M., Nawroth, P. N., Weigand, M. W., Hofer, S. H., Brenner, T. B., Fotopoulou, G., Poularas, I., Kokkoris, S., Brountzos, E., Elghonemi, M., Nilsson, K. F., Sandin, J., Gustafsson, L., Frithiof, R., Skorniakov, I., Varaksin, A., Vikulova, D., Shaikh, O., Whiteley, C., Ostermann, M., Di Lascio, G., Anicetti, L., Bonizzoli, M., Fulceri, G., Migliaccio, M. L., Sentina, P., Cozzolino, M., Peris, A., Khadzhynov, D., Halleck, F., Staeck, O., Lehner, L., Budde, K., Slowinski, T., Kindgen-Milles, D., Huysmans, N., Laenen, M. Vander, Helmschrodt, A., Boer, W., Debain, A., Jonckheer, J., Moeyersons, W., Van zwam, K., Puis, L., Staessens, K., Honoré, P. M., Spapen, H. D., De Waele, E., de Garibay, A. Perez Ruiz, Ende-Schneider, B., Schreiber, C., Kreymann, B., Bini, A., Votino, E., Steinberg, I., Vetrugno, L., Trunfio, D., Sidoti, A., Conroy, M., Marsh, B., and O’Flynn, J
- Subjects
Critical Care and Intensive Care Medicine ,Meeting Abstracts - Full Text
- View/download PDF
133. Does serum lactate combined with soluble endothelial selectins at ICU admission predict sepsis development?
- Author
-
Vassiliou, A. G., Mastora, Z., Edison Jahaj, Koutsoukou, A., Orfanos, S. E., and Kotanidou, A.
134. Effect of clarithromycin on septic patients
- Author
-
Evangelos Giamarellos-Bourboulis, Routsi, C., Raftogiannis, M., Kollias, S., Baziaka, F., Zervakis, D., Tsaganos, T., Orfanos, S., Armaganidis, A., Roussos, C., and Giamarellou, H.
135. Contribution of endocrine parameters in predicting outcome of multiple trauma patients in an intensive care unit
- Author
-
Ilias, I., Konstantinos Stamoulis, Armaganidis, A., Lyberopoulos, P., Tzanela, M., Orfanos, S., Theodorakopoulou, M., Tsagarakis, S., and Dimopoulou, I.
136. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
- Author
-
Paulzen M, Orfanos S, Gründer G, Paulzen, Michael, Orfanos, Stelios, and Gründer, Gerhard
- Published
- 2010
- Full Text
- View/download PDF
137. Poster session Thursday 12 December - PM: 12/12/2013, 14:00-18:00 * Location: Poster area
- Author
-
Garcia Martin, A, Fernandez Golfin, C, Salido Tahoces, L, Fernandez Santos, S, Jimenez Nacher, JJ, Moya Mur, JL, Velasco Valdazo, E, Hernandez Antolin, R, Zamorano Gomez, JL, Veronesi, F, Corsi, C, Caiani, EG, Lamberti, C, Tsang, W, Holmgren, C, Guo, X, Bateman, M, Iaizzo, P, Vannier, M, Lang, RM, Patel, AR, Adamayn, KG, Tumasyan, L R, Chilingaryan, AL, Nasr, G, Eleraki, A, Farouk, N, Axelsson, A, Langhoff, L, Jensen, MK, Vejlstrup, N, Iversen, K, Bundgaard, H, Watanabe, T, Iwai-Takano, M, Attenhofer Jost, C H, Pfyffer, M, Seifert, B, Scharf, C, Candinas, R, Medeiros-Domingo, A, Chin, J-Y, Yoon, HJ, Vollbon, W, Singbal, Y, Rhodes, K, Wahi, S, Katova, T M, Simova, I I, Hristova, K, Kostova, V, Pauncheva, B, Bircan, A, Sade, LE, Eroglu, S, Pirat, B, Okyay, K, Bal, U, Muderrisoglu, H, Heggemann, F, Buggisch, H, Welzel, G, Doesch, C, Hansmann, J, Schoenberg, S, Borggrefe, M, Wenz, F, Papavassiliu, T, Lohr, F, Roussin, I, Drakopoulou, M, Rosen, S, Sharma, R, Prasad, S, Lyon, AR, Carpenter, JP, Senior, R, Breithardt, O-A, Razavi, H, Arya, A, Nabutovsky, Y, Ryu, K, Gaspar, T, Kosiuk, J, Eitel, C, Hindricks, G, Piorkowski, C, Pires, S, Nunes, A, Cortez-Dias, N, Belo, A, Zimbarra Cabrita, I, Sousa, C, Pinto, F, Baron, T, Johansson, K, Flachskampf, FA, Christersson, C, Pires, S, Cortez-Dias, N, Nunes, A, Belo, A, Zimbarra Cabrita, I, Sousa, C, Pinto, F, Santoro, A, Federico Alvino, FA, Giovanni Antonelli, GA, Raffaella De Vito, RDV, Roberta Molle, RM, Sergio Mondillo, SM, Gustafsson, M, Alehagen, U, Johansson, P, Tsukishiro, Y, Onishi, T, Chimura, M, Yamada, S, Taniguchi, Y, Yasaka, Y, Kawai, H, Souza, J R M, Zacharias, L G T, Pithon, K R, Ozahata, T M, Cliquet, A JR, Blotta, M H, Nadruz, W JR, Fabiani, I, Conte, L, Cuono, C, Liga, R, Giannini, C, Barletta, V, Nardi, C, Delle Donne, MG, Palagi, C, Di Bello, V, Glaveckaite, S, Valeviciene, N, Palionis, D, Laucevicius, A, Hristova, K, Bogdanova, V, Ferferieva, V, Shiue, I, Castellon, X, Boles, U, Rakhit, R, Shiu, M F, Gilbert, T, Papachristidis, A, Henein, M Y, Westholm, C, Johnson, J, Jernberg, T, Winter, R, Ghosh Dastidar, A, Augustine, D, Cengarle, M, Mcalindon, E, Bucciarelli-Ducci, C, Nightingale, A, Onishi, T, Watanabe, T, Fujita, M, Mizukami, Y, Sakata, Y, Nakatani, S, Nanto, S, Uematsu, M, Saraste, A, Luotolahti, M, Varis, A, Vasankari, T, Tunturi, S, Taittonen, M, Rautakorpi, P, Airaksinen, J, Ukkonen, H, Knuuti, J, Boshchenko, A, Vrublevsky, A, Karpov, R, Yoshikawa, H, Suzuki, M, Hashimoto, G, Kusunose, Y, Otsuka, T, Nakamura, M, Sugi, K, Rosner, SJ, Orban, M, Lesevic, H, Karl, M, Hadamitzky, M, Sonne, C, Panaro, A, Martinez, F, Huguet, M, Moral, S, Palet, J, Oller, G, Cuso, I, Jornet, A, Rodriguez Palomares, J, Evangelista, A, Stoebe, S, Tarr, A, Pfeiffer, D, Hagendorff, A, Gilmanov, DSH, Baroni, MB, Cerone, EC, Galli, EG, Berti, SB, Glauber, MG, Soesanto, A, Yuniadi, Y, Mansyur, M, Kusmana, D, Venkateshvaran, A, Dash, P K, Sola, S, Govind, S C, Shahgaldi, K, Winter, R, Brodin, L A, Manouras, A, Dokainish, H, Sadreddini, M, Nieuwlaat, R, Lonn, E, Healey, J, Nguyen, V, Cimadevilla, C, Dreyfus, J, Codogno, I, Vahanian, A, Messika-Zeitoun, D, Lim, Y-J, Kawamura, A, Kawano, S, Polte, CL, Gao, S, Lagerstrand, KM, Cederbom, U, Bech-Hanssen, O, Baum, J, Beeres, F, Van Hall, S, Boering, YC, Zeus, T, Kehmeier, ES, Kelm, M, Balzer, JC, Della Mattia, A, Pinamonti, B, Abate, E, Nicolosi, GL, Proclemer, A, Bassetti, M, Luzzati, R, Sinagra, G, Hlubocka, Z, Jiratova, K, Dostalova, G, Hlubocky, J, Dohnalova, A, Linhart, A, Palecek, T, Sonne, C, Lesevic, H, Karl, M, Rosner, S, Hadamitzky, M, Ott, I, Malev, E, Reeva, S, Zemtsovsky, E, Igual Munoz, B, Alonso Fernandez Pau, PAF, Miro Palau Vicente, VMP, Maceira Gonzalez Alicia, AMG, Estornell Erill, JEE, Andres La Huerta, AALH, Donate Bertolin, LDB, Valera Martinez, FVM, Salvador Sanz Antonio, ASS, Montero Argudo Anastasio, AMA, Nemes, A, Kalapos, A, Domsik, P, Chadaide, S, Sepp, R, Forster, T, Onaindia, JJ, Arana, X, Cacicedo, A, Velasco, S, Rodriguez, I, Capelastegui, A, Sadaba, M, Gonzalez, J, Salcedo, A, Laraudogoitia, E, Archontakis, S, Gatzoulis, K, Vlasseros, I, Arsenos, P, Tsiachris, D, Vouliotis, A, Sideris, S, Karistinos, G, Kalikazaros, I, Stefanadis, C, Ancona, R, Comenale Pinto, S, Caso, P, Coppola, MG, Arenga, F, Cavallaro, C, Vecchione, F, Donofrio, A, Calabro, R, Correia, C E, Moreira, D, Cabral, C, Santos, JO, Cardoso, JS, Igual Munoz, B, Maceira Gonzalez, AMG, Estornell Erill Jordi, JEE, Jimenez Carreno, RJC, Arnau Vives, MAV, Monmeneu Menadas, JVMM, Domingo-Valero, DDV, Sanchez Fernandez, ESF, Montero Argudo Anastasio, AMA, Zorio Grima, EZG, Cincin, A, Tigen, K, Karaahmet, T, Dundar, C, Sunbul, M, Guler, A, Bulut, M, Basaran, Y, Mordi, I, Carrick, D, Berry, C, Tzemos, N, Cruz, I, Ferreira, A, Rocha Lopes, L, Joao, I, Almeida, AR, Fazendas, P, Cotrim, C, Pereira, H, Ochoa, J P, Fernandez, A, Filipuzzi, JM, Casabe, JH, Salmo, JF, Vaisbuj, F, Ganum, G, Di Nunzio, HJ, Veron, LF, Guevara, E, Salemi, VMC, Nerbass, FB, Portilho, N, Ferreira Filho, JCA, Pedrosa, RP, Arteaga-Fernandez, E, Mady, C, Drager, LF, Lorenzi-Filho, G, Marques, JS, Almeida, A M G, Menezes, M, Silva, GL, Placido, R, Amaro, C, Brito, D, Diogo, AN, Lourenco, M R, Azevedo, O, Moutinho, J, Nogueira, I, Machado, I, Portugues, J, Quelhas, I, Lourenco, A, Calore, C, Muraru, D, Melacini, P, Badano, LP, Mihaila, S, Puma, L, Peluso, D, Casablanca, S, Ortile, A, Iliceto, S, Kang, M-K, Yu, SH, Park, JJ, Kim, SH, Park, TY, Mun, H-S, C, S, Cho, S-R, Han, SW, Lee, N, Khalifa, E A, Hamodraka, E, Kallistratos, M, Zacharopoulou, I, Kouremenos, N, Mavropoulos, D, Tsoukas, A, Kontogiannis, N, Papanikolaou, N, Tsoukanas, K, Manolis, A, Villagraz Tecedor, L, Jimenez Lopez Guarch, C, Alonso Chaterina, S, Blazquez Arrollo, L, Lopez Melgar, B, Veitia Sarmiento, AL, Mayordomo Gomez, S, Escribano Subias, MP, Lichodziejewska, B, Kurnicka, K, Goliszek, S, Dzikowska Diduch, O, Kostrubiec, M, Krupa, M, Grudzka, K, Ciurzynski, M, Palczewski, P, Pruszczyk, P, Sakata, K, Ishiguro, M, Kimura, G, Uesugo, Y, Takemoto, K, Minamishima, T, Futuya, M, Matsue, S, Satoh, T, Yoshino, H, Signorello, MC, Gianturco, L, Colombo, C, Stella, D, Atzeni, F, Boccassini, L, Sarzi-Puttini, PC, Turiel, M, Kinova, E, Deliiska, B, Krivoshiev, S, Goudev, A, De Stefano, F, Santoro, C, Buonauro, A, Schiano-Lomoriello, V, Muscariello, R, De Palma, D, Galderisi, M, Ranganadha Babu, B, Chidambaram, SUNDAR, Sangareddi, V, Dhandapani, VE, Ravi, MS, Meenakshi, K, Muthukumar, D, Swaminathan, N, Ravishankar, G, Bruno, R M, Giardini, G, Catizzo, B, Brustia, R, Malacrida, S, Armenia, S, Cauchy, E, Pratali, L, Resamont2, Cesana, F, Alloni, M, Vallerio, P, De Chiara, B, Musca, F, Belli, O, Ricotta, R, Siena, S, Moreo, A, Giannattasio, C, Magnino, C, Omede, P, Avenatti, E, Presutti, D, Sabia, L, Moretti, C, Bucca, C, Gaita, F, Veglio, F, Milan, A, Eichhorn, JG, Springer, W, Helling, A, Alarajab, A, Loukanov, T, Ikeda, M, Kijima, Y, Akagi, T, Toh, N, Oe, H, Nakagawa, K, Tanabe, Y, Watanabe, N, Ito, H, Hascoet, S, Hadeed, K, Marchal, P, Bennadji, A, Peyre, M, Dulac, Y, Heitz, F, Alacoque, X, Chausseray, G, Acar, P, Kong, WILL, Ling, LH, Yip, JAMES, Poh, KK, Vassiliou, V, Rekhraj, S, Hoole, SP, Watkinson, O, Kydd, A, Boyd, J, Mcnab, D, Densem, C, Shapiro, LM, Rana, BS, Potpara, TS, Djikic, D, Polovina, M, Marcetic, Z, Peric, V, Lip, GYH, Gaudron, P, Niemann, M, Herrmann, S, Hu, K, Strotmann, J, Beer, M, Bijnens, B, Liu, D, Ertl, G, Weidemann, F, Peric, V, Jovanovic, A, Djikic, D, Otasevic, P, Kochanowski, J, Piatkowski, R, Scislo, P, Grabowski, M, Marchel, M, Opolski, G, Bandera, F, Guazzi, M, Arena, R, Corra, U, Ghio, S, Forfia, P, Rossi, A, Dini, F, Cahalin, LP, Temporelli, L, Rallidis, L, Tsangaris, I, Makavos, G, Anthi, A, Pappas, A, Orfanos, S, Lekakis, J, Anastasiou-Nana, M, Kuznetsov, V A, Krinochkin, D V, Yaroslavskaya, E I, Zaharova, E H, Pushkarev, G S, Mizia-Stec, K, Wita, K, Mizia, M, Loboz-Grudzien, K, Szwed, H, Kowalik, I, Kukulski, T, Gosciniak, P, Kasprzak, J, Plonska-Gosciniak, E, Cimino, S, Pedrizzetti, G, Tonti, G, Cicogna, F, Petronilli, V, De Luca, L, Iacoboni, C, Agati, L, Hoffmann, R, Barletta, G, Von Bardeleben, S, Kasprzak, J, Greis, C, Vanoverschelde, J, Becher, H, Galrinho, A, Moura Branco, L, Fiarresga, A, Cacela, D, Ramos, R, Cruz Ferreira, R, Van Den Oord, SCH, Akkus, Z, Bosch, JG, Renaud, G, Sijbrands, EJG, Verhagen, HJM, Van Der Lugt, A, Van Der Steen, AFW, Schinkel, AFL, Mordi, I, Tzemos, N, Stanton, T, Delgado, D, Yu, E, Drakopoulou, M, Gonzalez-Gonzalez, AM, Karonis, T, Roussin, I, Babu-Narayan, S, Swan, L, Senior, R, Li, W, Parisi, V, Pagano, G, Pellegrino, T, Femminella, GD, De Lucia, C, Formisano, R, Cuocolo, A, Perrone Filardi, P, Leosco, D, Rengo, G, Unlu, S, Farsalinos, K, Amelot, K, Daraban, A, Ciarka, A, Delcroix, M, Voigt, JU, Miskovic, A, Poerner, TD, Goebel, B, Stiller, CH, Moritz, A, Sakata, K, Uesugo, Y, Kimura, G, Ishiguro, M, Takemoto, K, Minamishima, T, Futuya, M, Satoh, T, Yoshino, H, Miyoshi, T, Tanaka, H, Kaneko, A, Matsumoto, K, Imanishi, J, Motoji, Y, Mochizuki, Y, Minami, H, Kawai, H, Hirata, K, Wutthimanop, A, See, O, Vathesathokit, P, Yamwong, S, Sritara, P, Rosner, A, Kildal, AB, Stenberg, TA, Myrmel, T, How, OJ, Capriolo, M, Frea, S, Giustetto, C, Scrocco, C, Benedetto, S, Grosso Marra, W, Morello, M, Gaita, F, Garcia-Gonzalez, P, Cozar-Santiago, P, Chacon-Hernandez, N, Ferrando-Beltran, M, Fabregat-Andres, O, De La Espriella-Juan, R, Fontane-Martinez, C, Jurado-Sanchez, R, Morell-Cabedo, S, Ridocci-Soriano, F, Mihaila, S, Piasentini, E, Muraru, D, Peluso, D, Casablanca, S, Puma, L, Naso, P, Iliceto, S, Vinereanu, D, Badano, LP, Tarzia, P, Villano, A, Figliozzi, S, Russo, G, Parrinello, R, Lamendola, P, Sestito, A, Lanza, GA, Crea, F, Sulemane, S, Panoulas, VF, Bratsas, A, Frankel, AH, Nihoyannopoulos, P, Dores, H, Andrade, MJ, Almeida, MS, Goncalves, PA, Branco, P, Gaspar, A, Gomes, A, Horta, E, Carvalho, MS, Mendes, M, Yue, WS, Li, XY, Chen, Y, Luo, Y, Gu, P, Yiu, KH, Siu, CW, Tse, HF, Cho, EJ, Lee, SH, Hwang, BH, Kim, DB, Jang, SW, Jeon, HK, Youn, HJ, and Kim, JH
- Abstract
Background: Progress in the technique of TAVR requires good knowledge of the aortic root. With this aim new specialized software appears, with the ability of automated quantitative modeling of the AV and root from 3D TEE.The purpose of this study was to validate this model with the measurements made manually. Methods: Eight patients undergoing TAVR in our center where included. The diameters of the aortic annulus, sinotubular union (STU) and sinus of valsalva (SV) were measured by 2D TEE; diameters and areas of aortic annulus, STU and SV as well as anatomic aortic valve area were measured by 3D TEE. Afterwards, the images were analyzed using the new software (Figure 1). Results. We showed good correlation with aortic annulus diameter measured by 2D TEE (r:,832 p:,01) and excellent correlation with one of the aortic annulus diameter measured by 3D TEE (r:,941 p:,00). The same happened with the area (r:,720 p:,04). Regarding the measurements at SV level, the correlations between the diameters by 2D TEE and 3D TEE with the measurements obtained with the new model were the following (r:,771;p:,025) and (r:,797;p:,018). The correlation of the area was also good (r:,812 p:,014).An excellent correlation was found between the measurements at UST level. UST diameter by 2D TEE (r:,818;P:,013), by ETE3D (r:,800;p:,017) and area (r:,844;p:,008).Finally, the anatomic aortic valve area measured by the new model showed significant correlation with the 3D TTE (r:,830 p:,011). Conclusions. There is a proper correlation between manual and automated measurements analyzed by the new model. The feasibility of determine the TAVR results with geometric models based on image, prior to procedure, is one of the possibilities of this new software. Prospective studies are necessary to define its applicability.
Figure 1 - Published
- 2013
- Full Text
- View/download PDF
138. Assessment of pulmonary capillary endothelial function in an ards patient on extracorporeal CO2 removal
- Author
-
Armaganidis, A., Orfanos, S. E., Sfyras, D., Kaltsas, P., Catravas, J. D., Economidou, J., and Roussos, Ch.
- Abstract
Conclusions These preliminary data i) confirm that PCEB ACE activity is reduced in ARDS, whereas it is not altered by ECCO
2 R application per se, and ii) suggest that PCEB ACE activity correlates with the clinical severity of ARDS and may serve as a quantifiable index of the severity of the syndrome and its response to treatment. (Supported by PENED No 70/2/1610, theThorax Foundation and HL31422).- Published
- 1996
- Full Text
- View/download PDF
139. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis.
- Author
-
Yogeswaran A, Gall H, Fünderich M, Wilkins MR, Howard L, Kiely DG, Lawrie A, Hassoun PM, Sirenklo Y, Torbas O, Sweatt AJ, Zamanian RT, Williams PG, Frauendorf M, Arvanitaki A, Giannakoulas G, Saleh K, Sabbour H, Cajigas HR, Frantz R, Al Ghouleh I, Chan SY, Brittain E, Annis JS, Pepe A, Ghio S, Orfanos S, Anthi A, Majeed RW, Wilhelm J, Ghofrani HA, Richter MJ, Grimminger F, Sahay S, Tello K, and Seeger W
- Abstract
Background: Pulmonary hypertension (PH) is a heterogeneous disease with a poor prognosis. Accurate risk stratification is essential for guiding treatment decisions in pulmonary arterial hypertension (PAH). Although various risk models have been developed for PAH, their comparative prognostic potential requires further exploration. Additionally, the applicability of risk scores in PH groups beyond group 1 remains to be investigated., Research Question: Are risk scores originally developed for PAH predictive in PH groups 1 through 4?, Study Design and Methods: We conducted a comprehensive analysis of outcomes among patients with incident PH enrolled in the multicenter worldwide Pulmonary Vascular Research Institute GoDeep meta-registry. Analyses were performed across PH groups 1 through 4 and further subgroups to evaluate the predictive value of PAH risk scores, including Registry to Evaluate Early and Long-Term PAH Disease Mangement (REVEAL) Lite 2, REVEAL 2.0, ESC/ERS 2022, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 3-strata, and COMPERA 4-strata., Results: Eight thousand five hundred sixty-five patients were included in the study, of whom 3,537 patients were assigned to group 1 PH, whereas 1,807 patients, 1,635 patients, and 1,586 patients were assigned to group 2 PH, group 3 PH, and group 4 PH, respectively. Pulmonary hemodynamics were impaired with median mean pulmonary arterial pressure of 42 mm Hg (interquartile range, 33-52 mm Hg) and pulmonary vascular resistance of 7 Wood units (WU) (interquartile range, 4-11 WU). All risk scores were prognostic in the entire PH population and in each of the PH groups 1 through 4. The REVEAL scores, when used as continuous prediction models, demonstrated the highest statistical prognostic power and granularity; the COMPERA 4-strata risk score provided subdifferentiation of the intermediate-risk group. Similar results were obtained when separately analyzing various subgroups (PH subgroups 1.1, 1.4.1, and 1.4.4; PH subgroups 3.1 and 3.2; group 2 with isolated postcapillary PH vs combined precapillary and postcapillary PH; patients of all groups with concomitant cardiac comorbidities; and severe [> 5 WU] vs nonsevere PH)., Interpretation: This comprehensive study with real-world data from 15 PH centers showed that PAH-designed risk scores possess predictive power in a large PH cohort, whether considered as common to the group or calculated separately for each PH group (1-4) and various subgroups., Trial Registry: ClinicalTrials.gov; No.: NCT05329714; URL: www., Clinicaltrials: gov., Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: A. Y. has received personal fees from MSD. H. G. has received personal fees from Actelion, AstraZeneca, Bayer, BMS, GossamerBio, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics. M. R. W. reports personal fees from MorphogenIX, Janssen, Chiesi, and Aerami; grants from British Heart Foundation and NIHR; and personal fees from MSD, Benevolent AI, and Tiakis Biotech, outside the submitted work. L. H. reports personal fees and nonfinancial support from Janssen and personal fees from MSD, Gossamer, and Altavant. D. G. K. reports support for the present manuscript from the Sheffield Biomedical Research Centre and consulting fees and other payments from Jansen Pharmaceuticals, Ferrer, Altavant, MSD, and United therapeutics. P. M. H. reports personal fees from Merck Co. S. Y. C. reports personal fees from Janssen, Bayer, Pfizer, United Therapeutics, and Acceleron Pharma and is a director, officer, and shareholder of Synhale Therapeutics. S. O. reports personal fees from MSD, Janssen, and Gallenica-Ferrer. H. A. G. has received fees from Actelion, AstraZeneca, Bayer, GSK, Janssen-Cilag, Lilly, Novartis, OMT, Pfizer, and United Therapeutics. M. J. R. has received support from Janssen Pharmaceutica and Bayer Pharma AG and speaker fees from Janssen Pharmaceutica and OMT. S. S. reports personal fees from Gossamer Bio, Merck, Keros, Janssen, United Therapeutics, and Liquidia. K. T. has received personal fees from Bayer, AstraZeneca, and Gossamer. W. S. has received consultancy fees from United Therapeutics, Tiakis Biotech AG, Liquidia, Pieris Pharmaceuticals, Abivax, Pfitzer, and Medspray BV. None declared (M. Fünderich, A.L., Y. S., O. T., A. J. S., R. T. Z., P. G. W., M. Frauendorf, A. Arvanitaki, G. G., K. S., H. R. C., R. F., I. A. G., E. B., J. S. A., A. P., S. G., A. Anthi, R. W. M., J. W., F. G.), (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
140. Temporal trends in laboratory parameters in survivors and non‑survivors of critical COVID‑19 illness and the effect of dexamethasone treatment.
- Author
-
Kokkoris S, Kanavou A, Katsaros D, Karageorgiou S, Kremmydas P, Gkoufa A, Ntaidou T, Giannopoulos C, Kardamitsi MA, Dimopoulou G, Theodorou E, Georgakopoulou VE, Spandidos DA, Orfanos S, Kotanidou A, and Routsi C
- Abstract
Although coronavirus disease 2019 (COVID-19)-induced changes in laboratory parameters in patients upon admission have been well-documented, information on their temporal changes is limited. The present study describes the laboratory trends and the effect of dexamethasone treatment on these parameters, in patients with COVID-19 in the intensive care unit (ICU). Routine laboratory parameters, namely white blood cell (WBC), neutrophil, lymphocyte and platelet (PLT) counts, fibrinogen, C-reactive protein (CRP), lactate dehydrogenase (LDH) and albumin concentrations, were recorded upon admission to the ICU and, thereafter, on days 3, 5, 10, 15 and 21; these values were compared between survivors and non-survivors, as well as between those who were treated with dexamethasone and those who were not. Among the 733 patients in the ICU, (mean age, 65±13 years; 68% males; ICU mortality rate 45%; 76% of patients treated with dexamethasone), the WBC and neutrophil counts were persistently high in all patients, without significant differences over the first 15 days. Initially, low lymphocyte counts exhibited increasing trends, but remained higher in survivors compared to non-survivors (P=0.01). The neutrophil-to-lymphocyte ratio (NLR) was persistently elevated in all patients, although it was significantly higher in non-survivors compared to survivors (P < 0.001). The PLT count was initially increased in all patients, although it was significantly decreased in non-survivors over time. The fibrinogen and LDH values remained similarly elevated in all patients. However, the increased levels of CRP, which did not differ between patients upon admission, further increased in non-survivors compared to survivors after day 10 (P=0.001). Declining trends in albumin levels over time, overall, with a significant decrease in non-survivors compared to survivors, were observed. Dexamethasone treatment significantly affected the temporal progression of fibrinogen and CRP in survivors and that of NLR in non-survivors. On the whole, the present study demonstrates that patients in the ICU with COVID-19 present persistently abnormal laboratory findings and significant differences in laboratory trends of NLR, CRP, PLT and albumin, but not in WBC and neutrophil count, and fibrinogen and LDH levels, between survivors and non-survivors. The temporal progression of fibrinogen, CRP and NLR is affected by dexamethasone treatment., Competing Interests: DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests., (Copyright: © Kokkoris et al.)
- Published
- 2023
- Full Text
- View/download PDF
141. Changes in Cortisol Secretion and Corticosteroid Receptors in COVID-19 and Non COVID-19 Critically Ill Patients with Sepsis/Septic Shock and Scope for Treatment.
- Author
-
Ilias I, Vassiliou AG, Keskinidou C, Vrettou CS, Orfanos S, Kotanidou A, and Dimopoulou I
- Abstract
Sepsis is associated with dysregulated cortisol secretion, leading to abnormal levels of cortisol in the blood. In the early stages of the condition, cortisol levels are typically elevated due to increased secretion from the adrenal glands. However, as the disease progresses, cortisol levels may decline due to impaired adrenal function, leading to relative adrenal insufficiency. The latter is thought to be caused by a combination of factors, including impaired adrenal function, decreased production of corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) by the hypothalamus and pituitary gland, and increased breakdown of cortisol. The dysregulation of cortisol secretion in sepsis is thought to contribute to the pathophysiology of the disease by impairing the body's ability to mount an appropriate inflammatory response. Given the dysregulation of cortisol secretion and corticosteroid receptors in sepsis, there has been considerable interest in the use of steroids as a treatment. However, clinical trials have yielded mixed results and corticosteroid use in sepsis remains controversial. In this review, we will discuss the changes in cortisol secretion and corticosteroid receptors in critically ill patients with sepsis/septic shock. We will also make special note of COVID-19 patients, who presented a recent challenge for ICU management, and explore the scope for corticosteroid administration in both COVID-19 and non-COVID-19 septic patients., Competing Interests: The authors report that they have no conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
142. Acetazolamide for Bipolar Disorders: A Scoping Review.
- Author
-
Strawbridge R, Yalin N, Orfanos S, and Young AH
- Abstract
Acetazolamide, a carbonic anhydrase inhibitor, is used to treat a variety of ailments. It has been highlighted for its potential to benefit people with bipolar disorders, for whom there are clear current unmet treatment needs. This scoping review sought to synthesise all available evidence related to the potential effects of acetazolamide on symptoms related to bipolar disorder, acceptability and tolerability, and intervention characteristics (e.g., dose and duration). Following publication of the review protocol, the Pubmed, Embase, and PsycInfo databases were searched (all dated to 31 August 2022). A systematic approach was undertaken to identify eligible articles and extract relevant data from these. Five studies were included, assessing a total of 50 patients treated with acetazolamide. Most patients were from two open-label trials, while the others were case reports. Approximately one third of patients were experiencing psychosis or mania before treatment initiation, and one third had refractory depression. Forty-four percent of patients were estimated to achieve a response (not seemingly affected by the baseline episode type, acetazolamide dose, or duration), while a further 22% appeared to experience minimal benefits from the intervention. Acetazolamide was generally reported to be tolerated well and acceptable for up to 2 years, although reporting for acceptability and tolerability was suboptimal. The reviewed evidence is extremely limited in size and methodology (e.g., no randomised studies, blinding, or standardised outcome assessment). We posit that the current findings are sufficiently encouraging to recommend substantive clinical trials, but we emphasise that at present, the evidence is exceedingly preliminary, and there remains evident uncertainty as to whether acetazolamide could be a viable treatment for bipolar disorders.
- Published
- 2023
- Full Text
- View/download PDF
143. Epinephrine evokes shortening of human airway smooth muscle cells following β 2 adrenergic receptor desensitization.
- Author
-
Deeney BT, Cao G, Orfanos S, Lee J, Kan M, Himes BE, Parikh V, Koziol-White CJ, An SS, and Panettieri RA Jr
- Subjects
- Adrenergic beta-Agonists, Bronchi, Bronchodilator Agents pharmacology, Epinephrine pharmacology, Humans, Muscle, Smooth, Receptors, Adrenergic, alpha-1, Myocytes, Smooth Muscle, Receptors, Adrenergic, beta-2
- Abstract
Epinephrine (EPI), an endogenous catecholamine involved in the body's fight-or-flight responses to stress, activates α
1 -adrenergic receptors (α1 ARs) expressed on various organs to evoke a wide range of physiological functions, including vasoconstriction. In the smooth muscle of human bronchi, however, the functional role of EPI on α1 ARs remains controversial. Classically, evidence suggests that EPI promotes bronchodilation by stimulating β2 -adrenergic receptors (β2 ARs). Conventionally, the selective β2 AR agonism of EPI was thought to be, in part, due to a predominance of β2 ARs and/or a sparse, or lack of α1 AR activity in human airway smooth muscle (HASM) cells. Surprisingly, we find that HASM cells express a high abundance of ADRA1B (the α1 AR subtype B) and identify a spontaneous "switch-like" activation of α1 ARs that evokes intracellular calcium, myosin light chain phosphorylation, and HASM cell shortening. The switch-like responses, and related EPI-induced biochemical and mechanical signals, emerged upon pharmacological inhibition of β2 ARs and/or under experimental conditions that induce β2 AR tachyphylaxis. EPI-induced procontractile effects were abrogated by an α1 AR antagonist, doxazosin mesylate (DM). These data collectively uncover a previously unrecognized feed-forward mechanism driving bronchospasm via two distinct classes of G protein-coupled receptors (GPCRs) and provide a basis for reexamining α1 AR inhibition for the management of stress/exercise-induced asthma and/or β2 -agonist insensitivity in patients with difficult-to-control, disease subtypes.- Published
- 2022
- Full Text
- View/download PDF
144. Group experiences of cognitive stimulation therapy (CST) in Tanzania: a qualitative study.
- Author
-
Morrish J, Walker R, Dotchin C, Spector A, Orfanos S, Mkenda S, and Shali EP
- Subjects
- Cognition physiology, Humans, Qualitative Research, Quality of Life psychology, Tanzania, Cognitive Behavioral Therapy, Dementia therapy
- Abstract
Background: Tanzania is a low-income country in which medication for dementia is largely unavailable. Cognitive Stimulation Therapy (CST) is a group-based psychological treatment for people with dementia (PwD), shown to improve cognition and quality of life (QoL). It has previously been culturally adapted and piloted in Tanzania, shown to produce similar outcomes. UK research into CST suggests processes inherent to the group nature are key to its success. This study sought to identify group processes within CST in Tanzania and understand their impact on CST principles and outcomes., Methods: Data collection took place in rural Hai District, through qualitative semi-structured interviews. Sixteen PwD and four facilitators were recruited through convenience sampling and interviewed about their experiences of CST. Interviews were audio-recorded, translated, transcribed and analysed by thematic analysis., Results: Two main themes emerged: 'Positive group experiences' and 'Negative group experiences'. From this, a number of group processes were identified, such as helping behaviours and feeling understood by the group. Positive processes supported CST principles and participant improvement. Facilitators were influential over group dynamics. The group processes identified impacted CST principles and treatment outcomes., Conclusions: This is the first study on group mechanisms of CST in Tanzania. It provides deeper insight into participants' experiences of CST, thus identifying specific processes underlying the quantitatively measured positive outcomes of CST in Tanzania by previous studies. It also reveals further cultural barriers to implementation, enabling amendments for optimization of treatment efficacy.
- Published
- 2022
- Full Text
- View/download PDF
145. MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.
- Author
-
Barrett CD, Moore HB, Moore EE, Benjamin Christie D 3rd, Orfanos S, Anez-Bustillos L, Jhunjhunwala R, Hussain S, Shaefi S, Wang J, Hajizadeh N, Baedorf-Kassis EN, Al-Shammaa A, Capers K, Banner-Goodspeed V, Wright FL, Bull T, Moore PK, Nemec H, Thomas Buchanan J, Nonnemacher C, Rajcooar N, Ramdeo R, Yacoub M, Guevara A, Espinal A, Hattar L, Moraco A, McIntyre R, Talmor DS, Sauaia A, and Yaffe MB
- Abstract
Background: Few therapies exist to treat severe COVID-19 respiratory failure once it develops. Given known diffuse pulmonary microthrombi on autopsy studies of COVID-19 patients, we hypothesized that tissue plasminogen activator (tPA) may improve pulmonary function in COVID-19 respiratory failure., Methods: A multicenter, retrospective, observational study of patients with confirmed COVID-19 and severe respiratory failure who received systemic tPA (alteplase) was performed. Seventy-nine adults from seven medical centers were included in the final analysis after institutional review boards' approval; 23 were excluded from analysis because tPA was administered for pulmonary macroembolism or deep venous thrombosis. The primary outcome was improvement in the PaO
2 /FiO2 ratio from baseline to 48 h after tPA. Linear mixed modeling was used for analysis., Results: tPA was associated with significant PaO2 /FiO2 improvement at 48 h (estimated paired difference = 23.1 ± 6.7), which was sustained at 72 h (interaction term p < 0.00). tPA administration was also associated with improved National Early Warning Score 2 scores at 24, 48, and 72 h after receiving tPA (interaction term p = 0.00). D-dimer was significantly elevated immediately after tPA, consistent with lysis of formed clot. Patients with declining respiratory status preceding tPA administration had more marked improvement in PaO2 /FiO2 ratios than those who had poor but stable (not declining) respiratory status. There was one intracranial hemorrhage, which occurred within 24 h following tPA administration., Conclusions: These data suggest tPA is associated with significant improvement in pulmonary function in severe COVID-19 respiratory failure, especially in patients whose pulmonary function is in decline, and has an acceptable safety profile in this patient population., (© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)- Published
- 2022
- Full Text
- View/download PDF
146. Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.
- Author
-
Douin DJ, Shaefi S, Brenner SK, Gupta S, Park I, Wright FL, Mathews KS, Chan L, Al-Samkari H, Orfanos S, Radbel J, and Leaf DE
- Subjects
- Adult, Critical Illness, Humans, Tissue Plasminogen Activator therapeutic use, COVID-19 Drug Treatment
- Published
- 2021
- Full Text
- View/download PDF
147. Thyroid hormone alterations in critically and non-critically ill patients with SARS-CoV-2 infection.
- Author
-
Vassiliadi DA, Ilias I, Pratikaki M, Jahaj E, Vassiliou AG, Detsika M, Ampelakiotou K, Koulenti M, Manolopoulos KN, Tsipilis S, Gavrielatou E, Diamantopoulos A, Zacharis A, Athanasiou N, Orfanos S, Kotanidou A, Tsagarakis S, and Dimopoulou I
- Abstract
Objective: Following the evolution of COVID-19 pandemic, reports pointed on a high prevalence of thyroiditis-related thyrotoxicosis. Interpretation of thyroid tests during illness, however, is hampered by changes occurring in the context of non-thyroidal illness syndrome (NTIS). In order to elucidate these findings, we studied thyroid function in carefully selected cohorts of COVID-19 positive and negative patients., Design: Cohort observational study., Methods: We measured TSH, FT4, T3 within 24 h of admission in 196 patients without thyroid disease and/or confounding medications. In this study, 102 patients were SARS-CoV-2 positive; 41 admitted in the ICU, 46 in the ward and 15 outpatients. Controls consisted of 94 SARS-CoV-2 negative patients; 39 in the ICU and 55 in the ward. We designated the thyroid hormone patterns as consistent with NTIS, thyrotoxicosis and hypothyroidism., Results: A NTIS pattern was encountered in 60% of ICU and 36% of ward patients, with similar frequencies between SARS-CoV-2 positive and negative patients (46.0% vs 46.8%, P = NS). A thyrotoxicosis pattern was observed in 14.6% SARS-CoV-2 ICU patients vs 7.7% in ICU negative (P = NS) and, overall in 8.8% of SARS-CoV-2 positive vs 7.4% of negative patients. In these patients, thyroglobulin levels were similar to those with normal thyroid function or NTIS. The hypothyroidism pattern was rare., Conclusions: NTIS pattern is common and relates to the severity of disease rather than SARS-CoV-2 infection. A thyrotoxicosis pattern is less frequently observed with similar frequency between patients with and without COVID-19. It is suggested that thyroid hormone monitoring in COVID-19 should not differ from other critically ill patients.
- Published
- 2021
- Full Text
- View/download PDF
148. A feasibility randomised control trial of individual cognitive stimulation therapy for dementia: impact on cognition, quality of life and positive psychology.
- Author
-
Gibbor L, Forde L, Yates L, Orfanos S, Komodromos C, Page H, Harvey K, and Spector A
- Subjects
- Cognition, Feasibility Studies, Humans, Psychology, Positive, Dementia therapy, Quality of Life
- Abstract
Objectives: This study aimed to evaluate the feasibility of a 14-session programme of individual Cognitive Stimulation Therapy (iCST) for people with dementia (PWD). It addressed potential limitations in previous literature of iCST and evaluated possible impact on cognition, quality of life (QoL) and positive psychology., Method: The 14-session iCST programme was developed using existing manuals for group and individual CST and consultation with experts in the field. Thirty-three PWD were recruited from care homes and randomly assigned to iCST (14, 45-min sessions) or treatment as usual (TAU) over seven weeks. Outcomes measures were assessed at baseline and follow-up after the intervention., Results: The intervention appeared feasible with high attendance to sessions, minimal levels of attrition, and ease of recruitment. Analysis of covariance indicated significant improvements in cognition (Alzheimer's Disease Assessment Scale-Cognitive subscale) for PWD receiving iCST compared to TAU. There were no significant differences between groups on follow-up scores on the standardised Mini Mental State Examination, measures of positive psychology or self- and proxy- reported QoL., Conclusion: A 14-session programme of iCST delivered by professionals was feasible and acceptable to PWD and may provide benefits to cognition. A larger randomised control trial would be necessary to fully evaluate intervention impact on cognition, as well as QoL and positive psychology.
- Published
- 2021
- Full Text
- View/download PDF
149. Group-based cognitive stimulation therapy for dementia: a qualitative study on experiences of group interactions.
- Author
-
Orfanos S, Gibbor L, Carr C, and Spector A
- Subjects
- Cognition, England, Humans, London, Dementia therapy, Quality of Life
- Abstract
Objectives: Cognitive Stimulation Therapy (CST) is an evidence-based group intervention shown to improve cognition and quality of life in dementia and is widely implemented across the NHS. However, no attempt has been made to understand the possible advantages, and/or disadvantages, of delivering CST in a group format. The main aim of the present study was to explore experiences of group interactions in CST and longer-term maintenance CST (MCST) groups., Method: A total of twenty-one semi-structured in-depth interviews were conducted across four separate groups delivered in London, the East Midlands, South West and South East of England; including two CST and two MCST groups. Group members with mild to moderate dementia and facilitators from these groups were interviewed. Thematic analysis was used to analyse the data using NVivo software., Results: The final analysis identified six themes: 'benefits and challenges of group expression', 'importance of companionship and getting to know others, 'togetherness and shared identity', 'group entertainment', 'group support' and 'cognitive stimulation through the group'. The inter-connecting relationship between these themes are synthesised and summarised., Conclusion: Findings support the notion that therapeutic advantages inherent to the group format exist in group-based CST. New insights into the challenges related to a group format are also highlighted and discussed. Future research may benefit from exploring the relationship between the identified experiences of group interactions and clinical outcomes.
- Published
- 2021
- Full Text
- View/download PDF
150. Analyzing Acute Care Surgery Patient Flow in the Emergency Department During COVID-19 Pandemic.
- Author
-
Feretzakis G, Karlis G, Tsekouras K, Orfanos S, Loupelis E, Petropoulou S, Mantzouranis K, Tsafaridou M, Chatzikyriakou R, Sofianou A, Zafeiriadou P, Tika A, Dalainas I, and Kaldis V
- Subjects
- Emergency Service, Hospital, Greece epidemiology, Humans, SARS-CoV-2, COVID-19, Pandemics
- Abstract
During the COVID-19 pandemic, the number of visits in emergency departments (ED) worldwide decreased significantly based on several studies. This study aims to compare the patient flow in the emergency surgery department during the COVID-19 pandemic and a control period in the emergency department of a public tertiary care hospital in Greece. The overall patient flow reduction regarding the ED visits between the two examined periods was 49.07%. The emergency surgery department's corresponding visits were 235 and 552, respectively, which indicated an overall patient flow decrease of 57.43%. Chi-square analysis showed that age groups and ambulance use had statistically significant associations with the periods examined. An independent samples t-test was applied and deduced that the average patient's age was statistically significantly higher in the COVID-19 pandemic than in the non-pandemic period. By analyzing hospital information system data, useful conclusions can be drawn to prepare a surgical emergency unit better and optimize resource allocation in a healthcare facility in similar critical situations.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.